


LAHIVE

&

COCKFIELD

L L P



COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DeCONTI, JR.  
ANN LAMPORT HAMMETTE  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DEANN FORAN SMITH  
PETER C. LAURO  
JEANNE M. DIGIORGIO  
DEBRA J. MILASINCIC, Ph.D.  
DAVID J. RIKKERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER

CYNTHIA L. KELLY, Ph.D.  
MEGAN E. WILLIAMS, Ph.D.  
RICHA NAND  
MICHAEL PHILLIPPS \*  
LISA M. DIROCCO  
HATHAWAY P. RUSSELL \*\*  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.  
PETER A. DIMATTIA  
VINCENT P. LOCICANO  
MERIDETH C. ARNOLD

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
WILLIAM A. SCOFIELD, JR.  
SIBLEY P. REPPERT

PATENT AGENTS  
THEODORE R. WEST  
SHAYNE Y. HUFF, Ph.D.  
DANIEL B. KU

TECHNICAL SPECIALISTS  
CYNTHIA M. SOROKA  
PETER W. DINI, Ph.D.  
EUIHOON LEE  
JENNIFER K. ROSENFIELD  
ALLAN TAMESHTIT, Ph.D.  
CATHERINE E. MCPHERSON  
ERIC F. WAGNER, Ph.D.  
SHAHID HASAN, Ph.D.  
JACOB G. WEINTRAUB  
JONATHAN M. SPARKS, Ph.D.  
CRISTIN E. HOWLEY, Ph.D.

\* Admitted in NY only  
\*\* Admitted in TX only

May 8, 2002

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Patent Application Serial No. 09/528,031  
Title: *Novel Multidrug Resistance-Associated Polypeptide*  
Filed: March 17, 2000  
Inventor: Andrew Shyjan  
Attorney Docket No. MNI-056CPCN

RECEIVED

MAY 28 2002

TECH CENTER 1600/2900

COPY OF PAPERS  
ORIGINALLY FILED

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Supplemental Information Disclosure Statement (in duplicate);
2. PTO Form 1449;
3. Copies of references cited in PTO Form 1449 (12); and
4. Return postcard.

Please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. *For this purpose, a duplicate of this sheet is attached.*

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

May 8, 2002

Date

Debra J. Milasincic, Esq., Reg. No. 46,931

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Debra J. Milasincic, Esq.  
Registration No. 46,931  
Attorney for Applicant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Andrew Shyjan

Serial No.: 09/528031

Filed: March 17, 2000

For: *Novel Multidrug Resistance-Associated Polypeptide*

Attorney Docket No.: MNI-056CPCN

# 15  
km  
8/12/08

Group Art Unit: 1642

Examiner: B. Brumback

RECEIVED

MAY 28 2002

COPY OF PAPERS  
ORIGINALLY FILED

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

May 8, 2002  
Date of Signature and of Mail Deposit

By:   
Debra J. Mnasincic, Esq.  
Reg. No. 46,931  
Attorney for Applicant

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicant and his attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A full copy of each cited publication is enclosed.


This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

05/24/2002 NMOKAMM1 00000105 120080 09528031

01 FC:126

180.00 CH

Inasmuch as this Information Disclosure Statement is being filed after January 2, 2002, the mailing date of the first office action in the instant application, please charge the \$240.00 fee pursuant to 37 CFR §1.97(c)(2) and §1.17(p) to our Deposit Order Account No. 12-0080 for the processing of this Supplemental Information Disclosure Statement. *For this purpose, a duplicate of this statement is also enclosed.*

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP  
  
Debra J. Milasincic, Esq.  
Registration No. 46,931  
Attorney for Applicant

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: **May 8, 2002**

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO <b>MNI-056CPCN</b>	SERIAL NO. <b>09/528053</b>
<b>LIST OF PUBLICATIONS CITED BY APPLICANT</b> (Use several sheets if necessary) <i>MAY 12 2002</i>		APPLICANT <b>Shyjan, Andrew</b>		FILING DATE <b>March 17, 2000</b>	GROUP <b>1642</b>
					<b>MAY 28 2002</b>

*RECEIVED*

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO

### OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	B1	✓ Genbank® Accession Number U83661 Human multidrug resistance-associated protein homolog (MRP5) mRNA, partial cds. 27-SEP-1997;
	B2	✓ Genbank® Accession Number 2439974 multidrug resistance-associated protein homolog [Homo sapiens] 26-SEP-1997;
	B3	✓ Genbank® Accession Number U83661 Human multidrug resistance-associated protein homolog (MRP5) mRNA, partial cds. 02-OCT-1997;
	B4	✓ Genbank® Accession Number AAB71758 multidrug resistance-associated protein homolog [Homo sapiens] 01-OCT-1997;
	B5	✓ Genbank® Accession Number U83661 Homo sapiens multidrug resistance protein 5 (MRP5) mRNA, complete cds. 03-AUG-1999;
	B6	✓ Genbank® Accession Number AAB71758 multidrug resistance protein 5 [Homo sapiens] 03-AUG-1999;
	B7	✓ Genbank® Accession Number U83661 Homo sapiens multidrug resistance protein 5 (MRP5) mRNA, complete cds. 03-AUG-1999;
	B8	✓ Genbank® Accession Number AAB71758 multidrug resistance protein 5 [Homo sapiens] 03-AUG-1999;
	B9	✓ Genbank® Accession Number U83661 Homo sapiens multidrug resistance protein 5 (MRP5) mRNA, complete cds. 21-JUN-2000;
	B10	✓ Genbank® Accession Number AAB71758 multidrug resistance protein 5 [Homo sapiens] 21-JUN-2000
	B11	✓ Wijnholds et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7476-81; and
	B12	✓ Kool et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997 Aug 15;57(16):3537-47.

Examiner	Date Considered
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.